This study is conducted as a pilot trial to assess the added benefit of the VeraSeal fibrin sealant to TXA on postoperative outcomes following TKR. Informed consent is obtained from all participants prior to inclusion in the study. Patients are prospectively recruited from a consecutive series of TKR procedures performed for end-stage osteoarthritis. Recruited patients were randomised into two cohorts: those receiving intra-articular tranexamic acid (TXA) alone, and those receiving intra-articular TXA and VeraSeal fibrin sealant (TXA+Sealant). Randomisation is performed just prior to surgery using a digital random allocation generator by the surgical team. Patients and physiotherapists responsible for outcome data collection are blinded to group allocation throughout the study period. Intraoperative administration of the sealant is performed after prosthetic implantation, which was followed by topical intra-articular TXA. In the TXA group, TXA is applied intraoperatively into the joint capsule prior to closure. In the TXA+Sealant group, VeraSeal was applied evenly onto subcutaneous tissues, synovium and exposed bony surfaces within the joint capsule and allowed to cure. The same dose of topical TXA was infiltrated after VeraSeal had cured, prior to closure. All other pathways were standard per hospital protocols. Preoperatively, demographic data including age, sex, height, and weight, as well as serum haemoglobin (Hb) levels were collected for all patients. Primary outcomes were collected on postoperative day 1: serum Hb, knee flexion range of motion (°), ambulation distance (m), and rest and ambulatory pain visual analogue scales (VAS) between 0 (no pain) and 10 (worst pain) were collected. All patients were inpatient during primary outcome data collection. Secondary outcomes included: Oxford Knee Score (0-48, higher is better), American Knee Society Score (0-100, higher is better), and SF-36 Score (0-100, higher is better), collected pre-operatively and 6 months post-operatively.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
78
Fibrin sealant contains human thrombin and fibrinogen, aiding platelet activation, aggregation, and fibrin clot formation.
Topical Tranexamic Acid (TXA) is an antifibrinolytic agent which stabilises clot formation and is infiltrated into local tissues perioperatively prior to closure.
Singapore General Hospital Department of Orthopaedics
Singapore, Singapore
Serum Hb
Serum Haemoglobin (g/dL)
Time frame: Preoperatively and one day after surgery
Knee Flexion ROM
Knee flexion range of motion (°)
Time frame: Preoperatively and one day after surgery
Ambulation Distance
Ambulation distance (m)
Time frame: One day after surgery
Rest Pain Score
Rest pain visual analogue scales (VAS) between 0 (no pain) and 10 (worst pain)
Time frame: One day after surgery
Ambulatory Pain Score
Ambulatory pain visual analogue scales (VAS) between 0 (no pain) and 10 (worst pain)
Time frame: One day after surgery
PROMs - OKS
Oxford Knee Score (0-48, higher is better)
Time frame: Pre-operatively and 6 months post-operatively
PROMs - AKSS
American Knee Society Score (0-100, higher is better)
Time frame: 6 months post-operatively
PROMs - SF-36
SF-36 Score (0-100, higher is better)
Time frame: 6 months post-operatively
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.